• Piezo1 Drives PANoptosis in Cardiac Ischemia/Reperfusion Inj

  2026-06-25

  The reference study reveals that the mechanosensitive Piezo1 channel exacerbates myocardial ischemia/reperfusion (I/R) injury by activating caspase-8-dependent PANoptosis in cardiomyocytes. These findings provide mechanistic insight into cardiac cell death pathways and highlight Piezo1 as a potential therapeutic target for ischemic heart disease.

• Canagliflozin Reshapes Mitochondria in Diabetic Kidney Model

  2026-06-25

  This study demonstrates that Canagliflozin, a selective SGLT2 inhibitor, induces profound structural and functional improvements in proximal tubular cell mitochondria in hypertensive–diabetic mice. These findings highlight a mitochondrial mechanism underlying renal protection, with implications for expanding research into diabetic kidney disease and metabolic modulation.

• Bifendate (DDB): Experimental Workflows for Hepatoprotection

  2026-06-24

  Bifendate (DDB) stands out as a robust hepatoprotection agent and autophagy inhibitor with unique multi-omics regulatory effects. This article delivers actionable workflows, optimization tips, and troubleshooting strategies for using bifendate in liver research, plus key insights from recent pharmacogenetic findings.

• Olsalazine Sodium: Applied Workflows in Inflammation & Cance

  2026-06-23

  Olsalazine Sodium stands out as a mesalamine dimer and potent LTB4 chemotaxis inhibitor, empowering translational scientists with precise, reproducible modulation of inflammatory and tumor biology. Its unique solubility profile and robust efficacy in both colorectal cancer models and xenobiotic transport assays make it a key tool for advanced research workflows.

• D-Luciferin: Advanced Principles for Quantitative Biolumines

  2026-06-23

  Explore the science behind D-Luciferin as a firefly luciferase substrate and its transformative role in quantitative bioluminescence imaging. This article offers a unique, in-depth analysis of assay design, practical applications, and insights from cutting-edge metastasis research.

• Protein A/G Magnetic Beads: Powering Next-Gen Vascular Disco

  2026-06-22

  Explore how APExBIO's Protein A/G Magnetic Beads unlock precision in antibody purification and protein-protein interaction analysis, driving breakthroughs in vascular epigenetics and translational research. This article delivers mechanistic insight, protocol guidance, and strategic foresight for researchers tackling complex cardiovascular biology.

• Etoposide (VP-16): Precision DNA Damage and Apoptosis Modeli

  2026-06-22

  Discover how Etoposide (VP-16) enables high-fidelity modeling of DNA double-strand breaks and apoptosis in cancer biology. This article unveils novel assay design strategies and practical insights, setting it apart from existing resources.

• Bifendate (DDB): Applied Hepatoprotection & Autophagy Contro

  2026-06-21

  Bifendate (DDB) stands out as an advanced hepatoprotection agent, uniquely combining potent lipid metabolism regulation and autophagy inhibition. This article delivers actionable workflows, troubleshooting strategies, and comparative insights to maximize experimental success with APExBIO’s Bifendate in liver research.

• Clodronate Liposomes: Precision In Vivo Macrophage Depletion

  2026-06-20

  Clodronate Liposomes from APExBIO enable researchers to dissect macrophage function with tissue and timing precision, supporting disease models from liver injury to tumor microenvironments. This reagent’s versatility across administration routes and compatibility with advanced mouse models set a new standard for immune cell modulation studies.

• Spiroplasma eriocheiris Entry Mechanisms in Drosophila S2 Ce

  2026-06-19

  Wei et al. (2019) reveal that Spiroplasma eriocheiris invades Drosophila S2 cells via clathrin-mediated endocytosis and macropinocytosis, not caveolae. This mechanistic insight advances invertebrate host-pathogen modeling and highlights cellular pathways crucial for infection and intervention.

• Mechanism to Medicine: Transforming Discovery with Bioactive

  2026-06-19

  This thought-leadership article explores how the DiscoveryProbe™ Bioactive Compound Library Plus (SKU: L1022P) empowers translational researchers to bridge mechanistic understanding and clinical application. By integrating mechanistic insight, peer-reviewed evidence, and strategic guidance for high-throughput screening, the piece provides actionable recommendations for target validation, pathway deconvolution, and early-stage drug discovery. The article uniquely escalates the field by synthesizing recent advances in ligand-receptor profiling, such as thermal shift assays, with robust compound diversity and workflow optimization, setting a new benchmark for translational impact.

• Neuroinflammatory Mechanisms in Trigeminal Neuralgia: The CG

  2026-06-18

  Liao et al. reveal that chronic trigeminal nerve root compression in rats triggers a neuroinflammatory cascade linking ATP-mediated Ca2+ signaling to upregulation of Piezo2 and key neuropeptides, driving mechanical allodynia. These findings highlight new therapeutic targets within the CGRP/SP-Piezo2 axis for neuropathic pain management.

• I-BET-762 BET Inhibitor: Applied Workflows in Ferroptosis &

  2026-06-18

  I-BET-762, a highly selective BET inhibitor from APExBIO, empowers researchers to dissect transcriptional regulation, model anti-inflammatory effects, and potentiate ferroptosis induction with quantitative precision. This article delivers actionable protocols, troubleshooting tips, and the latest evidence on how I-BET-762 uniquely advances preclinical epigenetics and cancer biology research.

• D-Luciferin Sodium Salt: Firefly Luciferase Substrate for Im

  2026-06-17

  D-Luciferin sodium salt is a high-purity bioluminescent substrate essential for ATP-dependent bioluminescence assays and non-invasive imaging. Its robust performance in cellular metabolism and viability monitoring supports advanced oncology and immunotherapy research.

• PDK4-IN-1 Hydrochloride: Selective PDK4 Inhibition in Metabo

  2026-06-17

  PDK4-IN-1 hydrochloride is a potent, orally active pyruvate dehydrogenase kinase 4 inhibitor with nanomolar efficacy and high selectivity. It enables precise modulation of PDH activity and mitochondrial energy metabolism in both in vitro and in vivo models. This article details its mechanistic rationale, evidence base, and optimal research integration strategies.

445 records 13/30 page Previous Next First page 上5页 1112131415 下5页 Last page